LifeArc – advancing innovation in rare disease

We act as a trusted partner to transform the way rare diseases are identified and treated.

LifeArc elects new Board Chair to drive charity’s ambitious strategy

Dr Ian Gilham appointed new Chair of Trustees to succeed Dr John Stageman when he steps down on 4 April after eight years.

New study explores unique approach to treat a rare liver disease

A research study looking into a new approach to treat primary sclerosing cholangitis (PSC) is progressing to clinical trials.

Celebrating our inspirational women scientists

Today is the UN’s International Day of Women and Girls in Science and we are delighted to have…

LifeArc bolsters scientific leadership by appointing new Chief Scientific Officer

Welcome to Dr Dave Powell, who has joined LifeArc as our first Chief Scientific Officer (CSO).  Dave is an experienced scientist and leader, with…

Reflecting on 2021 – a year of progress

As we bid farewell to another challenging year, we reflect on our work with partners and colleagues in 2021.

LifeArc appoints first Chief Operating Officer

Richard Godfrey has joined LifeArc as its first Chief Operating Officer (COO). The new role will strengthen…

LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases

Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.

LifeArc unveils new strategy and ÂŁ1.3 billion spend to drive life-changing science

Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.